Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

45.94 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Nov 20, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

82 83 Next >

What's Driving the Market Sentiment Around Bristol-Myers Squibb Co? ↗

November 20, 2025

Via Benzinga

Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices ↗

November 20, 2025

Via Stocktwits

Topics Workforce

Why GRAIL Stock Could Be Biotech’s Next Big Breakout ↗

November 19, 2025

Via MarketBeat

Market Movers in Motion: Merck & Co. and Amer Sports Chart Volatile Courses

November 18, 2025

The financial markets are a constant theater of dynamic shifts, and in recent months, two distinct players – pharmaceutical giant Merck & Co. and global sporting goods powerhouse Amer Sports – have...

Via MarketMinute

Topics Economy Initial Public Offering Intellectual Property

Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers

November 18, 2025

From Bristol Myers Squibb

Via Business Wire

Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q3

November 17, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Bristol-Myers Squibb (NYSE:BMY) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers

November 17, 2025

From Bristol Myers Squibb

Via Business Wire

1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky

November 16, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

These 2 Dividend ETFs Are a Retiree's Best Friend ↗

November 16, 2025

Exchange-traded funds provide investors with exposure to a basket of stocks. Some also pay dividends.

Via The Motley Fool

Topics Artificial Intelligence Bonds ETFs

Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗

November 14, 2025

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

Via Benzinga

Topics Artificial Intelligence

Stay informed with the top movers within the S&P500 index on Friday. ↗

November 14, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Discover which S&P500 stocks are making waves on Friday. ↗

November 14, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Tech Rebounds After Selloff, Bitcoin Craters To $97,000: What's Moving Markets Friday? ↗

November 14, 2025

Investors stepped back into beaten-down tech names Friday, with the Nasdaq 100 rising 0.6% by midday in New York, staging a modest rebound after Thursday's sharp selloff.

Via Benzinga

Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy ↗

November 14, 2025

Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and stroke studies continue with data expected in 2026.

Via Benzinga

Friday's session: gap up and gap down stock in the S&P500 index ↗

November 14, 2025

Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session.

Via Chartmill

Bristol Myers Slumps After Its Heart Condition Study Gets The Boot ↗

November 14, 2025

An independent data monitoring committee said the company's treatment for acute coronary syndrome was likely to fail in testing.

Via Investor's Business Daily

Discover the top S&P500 movers in Friday's pre-market session. ↗

November 14, 2025

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment.

Via Chartmill

BMY Stock Slumps 5% After It Scraps Heart Drug Study ↗

November 14, 2025

The decision follows an analysis by an independent data monitoring committee that the trial is unlikely to meet its key goal.

Via Stocktwits

Update on Phase 3 Librexia ACS Trial

November 14, 2025

From Bristol Myers Squibb

Via Business Wire

3 Reasons to Avoid BMY and 1 Stock to Buy Instead

November 13, 2025

While the S&P 500 is up 16.3% since May 2025, Bristol-Myers Squibb (currently trading at $48.73 per share) has lagged behind, posting a return of 10.4%. This might have investors contemplating their...

Via StockStory

Topics Stocks

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗

November 13, 2025

Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.

Via Benzinga

3 Healthcare Stocks Topping a 2025 List of Dividend Yields ↗

November 12, 2025

Turn health into wealth with these three high-yielding dividend stocks.

Via The Motley Fool

Jim Cramer Is Backing Off Bristol-Myers, But These 2 Chinese Stocks Are Good ↗

November 11, 2025

"Mad Money" host Jim Cramer discusses Bristol-Myers Squibb, Baidu, Alibaba, Brinker and New Era Energy & Digital.

Via Benzinga

Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern

November 10, 2025

San Diego, CA – November 10, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a dramatic collapse in its stock price, shedding nearly 50% of its value following the announcement of mixed results...

Via MarketMinute

Cliff Asness: The Stock Market is Expensive, Not a Bubble – A Call for Rationality in a Less Efficient Market

November 10, 2025

New York, NY – November 10, 2025 – In a financial landscape often characterized by extremes, Cliff Asness, the influential co-founder of AQR Capital Management, offers a nuanced yet stark assessment of...

Via MarketMinute

Topics Economy

Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes

November 05, 2025

From Bristol Myers Squibb

Via Business Wire

AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns

November 05, 2025

Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design...

Via TokenRing AI

Topics Artificial Intelligence Intellectual Property

10 Health Care Stocks Whale Activity In Today's Session ↗

November 03, 2025

Via Benzinga

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership ↗

November 03, 2025

BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization.

Via Benzinga

Cleveland-Cliffs, Meta And Rocket On CNBC's 'Final Trades' ↗

November 03, 2025

Cleveland-Cliffs shares gained 1.4% to close at $12.43 on Friday while Bristol-Myers Squibb shares gained 1% to close at $46.07.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

82 83 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Bristol-Myers Squibb (NY:BMY)

All News about Bristol-Myers Squibb

Starting at $3.75/week.

Subscribe Today